Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

    Access Status
    Fulltext not available
    Authors
    McNeil, J.
    Woods, R.
    Nelson, M.
    Murray, A.
    Reid, Christopher
    Kirpach, B.
    Storey, E.
    Shah, R.
    Wolfe, R.
    Tonkin, A.
    Newman, A.
    Williamson, J.
    Lockery, J.
    Margolis, K.
    Ernst, M.
    Abhayaratna, W.
    Stocks, N.
    Fitzgerald, S.
    Trevaks, R.
    Orchard, S.
    Beilin, L.
    Donnan, G.
    Gibbs, P.
    Johnston, C.
    Grimm, R.
    ASPREE Investigator Group
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    McNeil, J. and Woods, R. and Nelson, M. and Murray, A. and Reid, C. and Kirpach, B. and Storey, E. et al. 2017. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. The Journals of Gerontology series A. 72 (11): pp. 1586-1593.
    Source Title
    The Journals of Gerontology series A
    DOI
    10.1093/gerona/glw342
    ISSN
    1758-535X
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/56779
    Collection
    • Curtin Research Publications
    Abstract

    Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

    Related items

    Showing items related by title, author, creator and subject.

    • Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
      Ryan, Joanne; Storey, Elsdon; Murray, Anne M; Woods, Robyn L; Wolfe, Rory; Reid, Christopher ; Nelson, Mark R; Chong, Trevor TJ; Williamson, Jeff D; Ward, Stephanie A; Lockery, Jessica E; Orchard, Suzanne G; Trevaks, Ruth; Kirpach, Brenda; Newman, Anne B; Ernst, Michael E; McNeil, John J; Shah, Raj C; ASPREE Investigator Group (2020)
      OBJECTIVE: To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS: ...
    • Effect of aspirin on cancer incidence and mortality in older adults.
      McNeil, John J; Gibbs, Peter; Orchard, Suzanne G; Lockery, Jessica E; Bernstein, Wendy B; Cao, Yin; Ford, Leslie; Haydon, Andrew; Kirpach, Brenda; Macrae, Finlay; McLean, Catriona; Millar, Jeremy; Murray, Anne M; Nelson, Mark R; Polekhina, Galina; Reid, Christopher ; Richmond, Ellen; Rodríguez, Luz Maria; Shah, Raj C; Tie, Jeanne; Umar, Asad; van Londen, G.J.; Ronaldson, Kathlyn; Wolfe, Rory; Woods, Robyn L; Zalcberg, John; Chan, Andrew T; ASPREE Investigator Group (2020)
      BACKGROUND: ASPirin in Reducing Events in the Elderly (ASPREE), a randomized double-blind placebo-controlled trial (RCT) of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, ...
    • Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study
      Robman, L.; Guymer, R.; Woods, R.; Ward, S.; Wolfe, R.; Phung, J.; Hodgson, L.; Makeyeva, G.; Aung, K.; Gilbert, T.; Lockery, J.; Le-Pham, Y.; Orchard, S.; Storey, E.; Abhayaratna, W.; Reid, D.; Ernst, M.; Nelson, M.; Reid, Christopher; McNeil, J. (2017)
      Purpose: Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) is uncertain. The ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.